Clinical Trial Update: A Study of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Janssen's dengue vaccine candidate JNJ-64281802 against dengue serotype 1 in a human challenge model has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue

Drugs mentioned

• JNJ-64281802

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Healthy | Phase 2 | Status: WITHDRAWN